Literature DB >> 22709517

Pathogenesis of respiratory syncytial virus.

Sylvia van Drunen Littel-van den Hurk1, Ellen R Watkiss.   

Abstract

While affecting all age groups, respiratory syncytial virus (RSV) infections can be particularly severe in infants, who develop functionally distinct immune responses, as well as in immunocompromised individuals. The extent to which environmental, viral and host factors contribute to the pathogenesis of RSV varies considerably between infected individuals. A correlation between the level of virus replication and pathogenesis has been established, and several viral proteins, in particular NS1 and NS2, modulate the immune response. Host immunity clearly contributes to RSV pathogenesis, and a number of specific cell populations may be involved. Ultimately, whether the response induced by RSV is protective or pathogenic depends on a combination of host factors, young age being one of the most important ones.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709517     DOI: 10.1016/j.coviro.2012.01.008

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  34 in total

1.  Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.

Authors:  François Dalençon
Journal:  Hum Vaccin Immunother       Date:  2013-08-12       Impact factor: 3.452

2.  Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.

Authors:  Avraham Beigelman; Megan Isaacson-Schmid; Geneline Sajol; Jack Baty; Oscar M Rodriguez; Erin Leege; Kevin Lyons; Toni L Schweiger; Jie Zheng; Kenneth B Schechtman; Mario Castro; Leonard B Bacharier
Journal:  J Allergy Clin Immunol       Date:  2014-11-18       Impact factor: 10.793

Review 3.  Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity.

Authors:  Paul M Brown; Dana L Schneeberger; Giovanni Piedimonte
Journal:  Paediatr Respir Rev       Date:  2015-05-23       Impact factor: 2.726

Review 4.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

Review 5.  The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders.

Authors:  Keesha M Matz; R Marena Guzman; Alan G Goodman
Journal:  Int Rev Cell Mol Biol       Date:  2018-09-25       Impact factor: 6.813

Review 6.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

7.  Viral disruption of olfactory progenitors is exacerbated in allergic mice.

Authors:  R Ueha; S Mukherjee; S Ueha; D E de Almeida Nagata; T Sakamoto; K Kondo; T Yamasoba; N W Lukacs; S L Kunkel
Journal:  Int Immunopharmacol       Date:  2014-07-02       Impact factor: 4.932

8.  Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.

Authors:  Valeria Cagno; Manuela Donalisio; Andrea Civra; Marco Volante; Elena Veccelli; Pasqua Oreste; Marco Rusnati; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

9.  Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.

Authors:  Teresa R Johnson; David Rangel; Barney S Graham; Douglas E Brough; Jason G Gall
Journal:  Mol Ther       Date:  2013-06-10       Impact factor: 11.454

10.  Interactive effects of age and respiratory virus on severe lower respiratory infection.

Authors:  N Prasad; A A Trenholme; Q S Huang; M G Thompson; N Pierse; M A Widdowson; T Wood; R Seeds; S Taylor; C C Grant; E C Newbern
Journal:  Epidemiol Infect       Date:  2018-07-26       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.